Memuat...

Advertisement

Akebia Therapeutics Resubmits NDA For Vadadustat To FDA

RTTNews | 677 hari yang lalu

Akebia Therapeutics Resubmits NDA For Vadadustat To FDA

(RTTNews) - Biopharmaceutical company Akebia Therapeutics, Inc. (AKBA) announced Thursday it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.

Vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is currently approved for use in 35 countries.

Based on standard NDA resubmission review timelines, a letter from the FDA acknowledging that the resubmission is complete, classifying the resubmission, and setting the PDUFA date is expected in 30 days. Akebia expects the FDA to set a PDUFA date of six months from the date of submission.

For More Such Health News, visit rttnews.com

Teg: AKBA

read more

Akebia Therapeutics Expects To Resubmit NDA For Vadadustat NDA In Q3

Akebia Therapeutics Expects To Resubmit NDA For Vadadustat NDA In Q3

Biopharmaceutical company Akebia Therapeutics, Inc. (AKBA) announced Thursday that the company expects to resubmit its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease in adult patients on dialysis by the end of the third quarter of 2023.

RTTNews | 712 hari yang lalu

Pound Rises Against Majors

Pound Rises Against Majors

The British pound strengthened against other major currencies in the European session on Tuesday.

RTTNews | 5 minit yang lalu

DAX Up Nearly 0.8%; Infineon Rises Sharply On Strong Earnings

DAX Up Nearly 0.8%; Infineon Rises Sharply On Strong Earnings

German stocks are up in positive territory on Tuesday, gaining for a second straight session, as investors continue to focus on earnings and other corporate news, even while continuing to follow the developments on the trade front ahead of new tariffs that come into force later in the week.

RTTNews | 7 minit yang lalu

Yen Rises Amid BoJ Rate Hike Speculation

Yen Rises Amid BoJ Rate Hike Speculation

The Japanese yen strengthened against other major currencies in the Asian session on Tuesday, as the Bank of Japan's (BoJ) meeting minutes suggest the possibility of interest rate increases, contingent upon the anticipated performance of the economy and price.

RTTNews | 19 minit yang lalu

Sensex, Nifty End Modestly Lower After Trump's Tariff Threat

Sensex, Nifty End Modestly Lower After Trump's Tariff Threat

Indian shares ended Tuesday's session lower after U.S. President Donald Trump threatened to "substantially" raise tariffs on goods imported from India, accusing that the country profited from Russia's war in Ukraine by purchasing large quantities of Russian oil and reselling it on the global market.

RTTNews | 37 minit yang lalu

European Shares Rise Amid Fed Rate Cut Hopes, Earnings Deluge

European Shares Rise Amid Fed Rate Cut Hopes, Earnings Deluge

European stocks advanced on Monday as investors digested a slew of earnings updates and held onto hopes that the U.S. Federal Reserve may soon pivot to monetary easing.

RTTNews | 1j 37min yang lalu

Asian Shares Extend Gains Amid Fed Rate Cut Hopes

Asian Shares Extend Gains Amid Fed Rate Cut Hopes

Asian stocks rose for a second consecutive session on Tuesday after a Federal Reserve official said the time is nearing for rate cuts.

RTTNews | 2j 18min yang lalu

Yen Rises Against Majors

Yen Rises Against Majors

The Japanese yen strengthened against other major currencies in the Asian session on Tuesday.

RTTNews | 2j 27min yang lalu

Syarat | Privasi | Peta Laman | Site Map Calendar

&salin; 2025 Myfxbook Ltd. Hak Cipta Terpelihara.

PERINGATAN RISIKO TINGGI: Perdagangan pertukaran mata wang asing mempunyai risiko tinggi yang mungkin tidak sesuai untuk semua jenis pelabur. Leveraj menimbulkan risiko dan kerugian tambahan. Sebelum anda memutuskan untuk berdagang pertukaran mata wang asing, pertimbangkan dengan teliti objektif pelaburan, tahap pengalaman dan toleransi risiko anda. Anda berkemungkinan kehilangan sebahagian atau semua pelaburan awal anda. Jangan melaburkan wang yang anda tidak mampu untuk kehilangan. Didik diri anda tentang risiko yang berkaitan dengan perdagangan pertukaran asing, dan dapatkan nasihat daripada penasihat bebas kewangan atau cukai jika anda mempunyai sebarang pertanyaan mengenainya. Semua data dan maklumat yang disediakan adalah semata-mata untuk tujuan maklumat, dan bukan bertujuan untuk tujuan perdagangan atau nasihat. Prestasi masa lalu tidak semestinya menunjukkan hasil masa depan.